Dr Per Bäckman has 30 years of experience in developing inhaled medicines and has published +35 papers. Since 2010, Dr Bäckman has been mainly focused on the development and application of physiology-based biopharmaceutical models to enable understanding of the in vitro-in vivo relationships governing the exposure of inhaled medicines. Dr Bäckman is the founder and owner of Per Backman Consulting and provide services to Clients either through his own company or through the co-owned Medicon Valley Inhalation Consortium (MVIC). Dr Bäckman is also the co-chair of the PQRI working group to develop and establish the Biopharmaceutical Classification System for inhaled medicines (iBCS).